The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Seattle Genetics Inc

  • SGEN
  • NASDAQ
  • Consumer Products
  • Latest 35.95
  • Currency US$
  • Change 0.35
  • Percent Change 0.983 %
  • Volume 935,702
  • Fri Oct 24, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 35.52
  • Previous Close 35.60
  • High 36.31
  • Low 34.92
  • Bidx10 35.92
  • Askx2 37.13
  • 52-week High02/28 55.99
  • 52-week Low10/13 30.80
  • Beta 2.171
  • Market Cap 4,421.13M
  • EPS -0.59
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $280,210,000
  • Earnings $-62,560,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $44,810,000
  • Current Ratio 4.34

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $476,070,000
  • Liabilities $245,070,000
  • Liabilities-to-Equity Ratio 1.06

Price Ratios

  • Price to Sales 15.78
  • Price to Book 19.14
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Jul 31 $-0.22 Oct 30 $-0.25
Surprises Jul 31 -36.36% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Oct 24, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Seatlle Genetic develops monoclonal antibody-based drugs to treat cancer and related diseases. Using its monoclonal antibody-based technologies and its expertise in cancer, the company have assembled a portfolio of drug candidates targeted to many types of human cancers. The company utilizes its monoclonal antibody-based technologies to increase the potency and efficacy of antibodies with specificity for cancer. The company is testing our two most advanced product candidates, SGN-15 and SGN-10, in patients with breast, colon, prostate or other cancers.

Related Securities
Symbol Type Latest % Chg

Officers

  • Clay B. Siegall Director; President & CEO
  • Todd E. Simpson Chief Financial Officer
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

21823 30TH DRIVE SE SUITE
BOTHELL, WA
98021

Phone: (425)-527-4000
Fax: (425)-5274001

ppinkston@seagen.com
www.seattlegenetics.com

Ideas & Discussion

Live Discussion of SGEN on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.